Leukemia  >>  Phase 1
Welcome,         Profile    Billing    Logout  

841 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukemia
NCT05731219: UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
18
RoW
B7-H3 target, CAR gene modified gdT cell injection, UTAA06 injection
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia
09/23
09/25
NCT04245722: FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Terminated
1
98
US
FT596, Cyclophosphamide, Fludarabine, Rituximab, Rituxan, Truxima, Ruxience, Obinutuzumab, Gazyva, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
09/23
09/23
NCT02957032: A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Terminated
1
30
Europe
F16IL2, cytarabine
Philogen S.p.A.
Acute Myeloid Leukemia, Relapsed, Adult
09/23
09/23
NCT02146924: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

Active, not recruiting
1
71
US
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes, CD19-CAR-specific/truncated EGFR Lentiviral Vector-transduced T Cells, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T Cells, CD19R(EQ)28zeta/EGFRt+ TCM, CD19R(EQ)28zeta/truncated Human EGFR+ Central Memory T Cells, CD19R:CD28:lentiviral/EGFRt+ T Cells, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells, CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells, CD19R(EQ)28zetaEGFRt+ Tn/mem Cells, Laboratory Biomarker Analysis
City of Hope Medical Center, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
09/24
09/24
NCT04136275: CAR-37 T Cells In Hematologic Malignancies

Completed
1
6
US
CAR-37 T cells
Marcela V. Maus, M.D.,Ph.D.
Hematologic Malignancy, Leukemia, Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin
09/23
03/24
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Active, not recruiting
1
160
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
02/24
12/24
NCT04070768: Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Active, not recruiting
1
18
US
Gemtuzumab Ozogamicin, GO, Venetoclax
John Quigley, Pfizer, AbbVie
Acute Myeloid Leukemia
10/23
10/24
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Active, not recruiting
1
80
US
CG-806
Aptose Biosciences Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
02/24
12/24
NCT04554381: Assesment of JL1 Expression in Acute Leukemia

Not yet recruiting
1
50
NA
JL1 antigen
Assiut University
Acute Lymphoblastic Leukemia
10/23
11/23
NCT05961696: A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Withdrawn
1
22
US
Mosunetuzumab, RO7030816
M.D. Anderson Cancer Center, Genentech, Inc.
Refractory B-cell Acute Lymphoblastic Leukemia
10/23
10/23
NCT05712278: A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Terminated
1
7
US
SAR445419, fludarabine, fludara, cytarabine, cytosar-U
Sanofi
Acute Myeloid Leukaemia
02/24
03/24
NCT04336982: A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Terminated
1
22
Europe, Canada, US
CC-90009, Venetoclax, Azacitidine, Gilteritinib
Celgene, AbbVie
Leukemia, Myeloid, Acute
10/23
04/24
NCT03760523: Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

Terminated
1
27
US
Minnelide
H. Lee Moffitt Cancer Center and Research Institute, Minneamrita Therapeutics LLC
Acute Myeloid Leukemia
10/23
10/23
JSP-CP-003, NCT04429191: JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Recruiting
1
40
US
Humanized anti-CD117 Monoclonal Antibody (JSP191), JSP191
Jasper Therapeutics, Inc.
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
10/23
12/23
NCT04173988: Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Active, not recruiting
1
6
RoW
alloCART-19, allogeneic CAR-T19, Cyclophosphamide, no other intervention names, Fludarabine
Children's Hospital of Fudan University
ALL, Childhood B-Cell
10/24
07/25
NCT04473911: Haplo Peripheral Blood Sct In GVHD Prevention

Active, not recruiting
1
25
US
FLUDARABINE, Fludara®, CYCLOPHOSPHAMIDE, Cytoxan®, Neosar®, TBI, Melphalan, Alkeran®, L-PAM, L-Sarcolysin, Phenylalanine Mustard, Sirolimus, Rapamune, Mycophenolate mofetil, CellCept, Myfortic, RGI-2001
Zachariah Michael DeFilipp, Regimmune Corporation
GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma
10/23
10/24
FT516-101, NCT04023071: FT516 in Subjects With Advanced Hematologic Malignancies

Terminated
1
72
US
FT516, Rituximab, Rituxan, MabThera, Obinutuzumab, Gazyva, Cyclophosphamide, Fludarabine, IL-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Acute Myelogenous Leukemia, B-cell Lymphoma
10/23
10/23
NCT05574608: Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Recruiting
1
12
RoW
CD123-CAR-NK cells
Affiliated Hospital to Academy of Military Medical Sciences, Beijing JD Biotech Co. LTD.
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent
10/23
10/24
NCT03900598: A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
1
226
Europe, Japan, US, RoW
JNJ-67856633
Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
12/24
01/26
NCT04540796: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
1
147
Europe, US, RoW
JNJ-75348780
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
04/25
05/25
NCT04628338: IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Completed
1
8
US
IFN-γ (interferon gamma-1b) injection, ACTIMMUNE®
Sawa Ito, MD, Horizon Pharma USA, Inc.
Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
10/23
10/23
NCT05727683: CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Recruiting
1
33
RoW
CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, Fludarabine, Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Acute Lymphocytic Leukemia
10/23
07/25
NCT03595917: ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Recruiting
1
40
US
ABL001, Dasatinib, Sprycel, Prednisone, Blinatumomab
Marlise Luskin, MD, Novartis
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
11/25
11/26
NCT04532203: A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Recruiting
1
72
RoW
CAR-T cells, CAR-T cells injection, Ommaya Reservoir
Zhejiang University
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
11/23
11/26
NCT04532281: A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Recruiting
1
120
RoW
Murine CD19 CAR-T cells, Murine CD19 CAR-T cells injection
Zhejiang University, Yake Biotechnology Ltd.
Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue
11/23
11/26
NCT04603872: CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Recruiting
1
120
RoW
CD19/BCMA Targeted CAR T-cells and dasatinib, Administration of CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells, CD19/BCMA Targeted CAR T-cells infusion
Zhejiang University, Yake Biotechnology Ltd.
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
11/23
11/26
NCT05519384: Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Recruiting
1
12
RoW
JK500 cell injection，cyclophosphamide，Fludarabine
Institute of Hematology & Blood Diseases Hospital, Bejing Institute for Stem Cell and Regenerative Medicine, Institute for Stem cell and Regeneration, Chinese Academy of Sciences
Acute Myeloid Leukemia, Childhood, Relapsed Leukemia, Refractory Leukemia
11/23
12/25
NCT03939585: Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

Not yet recruiting
1
10
US
Cellular therapy product
Leland Metheny
Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Lymphoproliferative Disorders
06/25
06/26
NCT04876092: A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Active, not recruiting
1
45
Europe
JNJ-67856633, Ibrutinib, JNJ-54179060
Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
11/24
11/24
NCT04599543: IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Not yet recruiting
1
36
RoW
IL3 CAR T-cells, IL3 CAR-T cells injection
Zhejiang University, Yake Biotechnology Ltd.
Acute Myeloid Leukemia
11/23
11/26
NCT04609241: CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Not yet recruiting
1
72
RoW
CD79b CAR-T Cells
Zhejiang University, Yake Biotechnology Ltd.
Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
11/23
11/26
NCT04681105: Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Active, not recruiting
1
13
US
Acetaminophen, APAP, Paracetamol, Tylenol, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Diphenhydramine, FAR 90X2, PM 255, Probedryl, Rigidyl, S51, Syntedril, Flotetuzumab, CD123 x CD3 DART Bi-Specific Antibody MGD006, CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006, MGD006, RES234, S80880, Ibuprofen, (.+ -.)-p-Isobutylhydratropic acid, Advil, Motrin, p-Isobutylhydratropic acid, Ranitidine
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
05/26
05/26
AUTO1-PY1, NCT06173518: A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Recruiting
1
24
Europe, US
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
11/27
11/27
ChiCTR2100052009: A clinical study on the safety and effectiveness of CD19 CAR-T and CD22 CAR-T sequential treatment of relapsed and refractory acute B lymphocytic leukemia

Recruiting
1
36
 
CAR-T cell therapy
the First Affiliated Hospital, Zhejiang University School of Medicine; the First Affiliated Hospital, Zhejiang University School of Medicine, National Natural Science Foundation of China
Relapsed and refractory acute B lymphocytic leukemia
 
 
NCT01588015: Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Completed
1
36
US
tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cytomegalovirus Infection, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Isolated Plasmacytoma of Bone, Monoclonal Gammopathy of Undetermined Significance, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Multiple Myeloma, Stage I Small Lymphocytic Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
02/24
02/24
CD5CAR-T, NCT04594135: Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

Recruiting
1
20
RoW
anti-CD5 CAR T cells
iCell Gene Therapeutics, iCAR Bio, Peking University Shenzhen Hospital
T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma
11/23
11/23
NCT00819546: RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Checkmark P1 data - ASH 2012
Nov 2012 - Nov 2012: P1 data - ASH 2012
Active, not recruiting
1
29
US
RAD001, everolimus, PKC412, midostaurin
Richard Stone, MD, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Novartis
Acute Myeloid Leukemia, Myelodysplastic Syndrome
12/25
12/25
NCT02333162: Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recruiting
1
30
US
Fludarabine Phosphate, 2-F-ara-AMP, Beneflur, SH T 586, Melphalan, Alkeran, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Total Marrow Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, HSC, HSCT, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic BMT, Tacrolimus, Advagraf, FK 506, Mycophenolate Mofetil, Cellcept, MMF, Laboratory Biomarker Analysis
University of Chicago, National Cancer Institute (NCI)
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
12/28
12/28
NCT02508038: Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Recruiting
1
22
US
TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate, Zoledronic Acid, Zometa
University of Wisconsin, Madison
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Osteosarcoma, Neuroblastoma
12/24
12/25
NCT03063944: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Completed
1
37
US
STAT Inhibitor OPB-111077, OPB-111077, Decitabine, 2'-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 2353-33-5, 5-Aza-2'-deoxycytidine, 5-Aza-2'deoxycytidine, 5-Aza-2-deoxycytidine, 5-Azadeoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Venetoclax, 1257044-40-8, 4-(4-((2-(4-Chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Otsuka America Pharmaceutical
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
01/24
03/24
NCI-2018-00315, NCT03479268: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Active, not recruiting
1
18
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
06/24
06/24
NCT03740334: Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Active, not recruiting
1
45
US
Ribociclib, LEE011, Dexamethasone, Everolimus, Zortress
Dana-Farber Cancer Institute, Novartis
Acute Lymphoblastic Leukemia ALL
03/23
09/24
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL

Recruiting
1
129
US
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
03/26
03/28
NCT03955783: Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

Active, not recruiting
1
78
US
Venetoclax, Selinexor
Sanjay Mohan, Karyopharm Therapeutics Inc, AbbVie
Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
09/24
12/24
NCT03940352: HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Active, not recruiting
1
52
Europe, US, RoW
HDM201, MBG453, Venetoclax
Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
06/24
06/24
NCT04034446: CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Active, not recruiting
1
2
RoW
CD19-CD22 CAR-T cells
Institute of Hematology & Blood Diseases Hospital, Juventas Cell Therapy Ltd.
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
12/23
12/23
BR-101801-CT-101, NCT04018248: BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Active, not recruiting
1
30
US, RoW
BR101801 (Phase Ia), BR101801 (Phase Ib)
Boryung Pharmaceutical Co., Ltd
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, B Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Peripheral T Cell Lymphoma
09/23
03/24
LP-108-I-01, NCT04356846: A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Recruiting
1
74
RoW
LP-108 tablet
The First Affiliated Hospital with Nanjing Medical University, Guangzhou Lupeng Pharmaceutical Company LTD., Newave Pharmaceutical Inc
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
12/23
12/23
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT04512105: Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Active, not recruiting
1
6
US
Pitavastatin, LIVALO®, Venetoclax, VENCLEXTA®
University of California, Irvine, United States Department of Defense
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL, CLL, Relapsed, CLL, Refractory
04/23
06/24
NVG111-101, NCT04763083 / 2020-000820-20: First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Recruiting
1
90
Europe
NVG-111
NovalGen Ltd.
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Malignant Melanoma
12/23
12/25
NKX019-101, NCT05020678: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Recruiting
1
150
US, RoW
NKX019
Nkarta Inc.
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
08/24
12/38
ANCHOR2, NCT05487651: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

Recruiting
1
36
US
KUR-502, CD19.CAR-aNKT cells
Athenex, Inc.
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
12/23
12/24
NCT05297123: Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid

Recruiting
1
30
RoW
All-trans retinoic acid, ATRA, Arsenic Trioxide, ATO, Realgar-Indigo naturalis formula, RIF
First Affiliated Hospital Xi'an Jiaotong University
Acute Myeloid Leukemia
12/23
12/23
ChiCTR2000040641: CD7-CAR T cells for refractory/relapsed acute T lymphocytic leukemia Single center, bridging allogeneic hematopoietic stem cell transplantation after treatment remission Open, non-randomized, single-arm clinical trial

Recruiting
1
20
 
Cell reinfusion
Beijing Boren Hospital; Beijing Boren Hospital, Self-funded
Refractory/relapsed acute T lymphocytic leukemia
 
 
NCT03969446: Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Recruiting
1
54
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
11/25
11/25
CARDINAL, NCT06163430: - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

Not yet recruiting
1
80
US
TERN-701
Terns, Inc.
Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
11/25
05/26
NCT02446964: Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia

Active, not recruiting
1
24
US
Bone Marrow Transplantation, BMT, Bone Marrow Grafting, Bone Marrow Transplant, Marrow Transplantation, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, Oforta, SH T 586, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Cellcept, MMF, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation, Tacrolimus, FK 506, Fujimycin, Prograf, Protopic, Total Marrow Irradiation
City of Hope Medical Center, National Cancer Institute (NCI)
Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Complete Remission
06/24
06/24
NCI-2014-01147, NCT02159495: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Hourglass Jul 2021 - Dec 2021 : Updated data for r/r AML and r/r BPDCN
Checkmark In CD123+ r/r AML and persistent/recurrent BPDCN at ASH 2018
Nov 2018 - Nov 2018: In CD123+ r/r AML and persistent/recurrent BPDCN at ASH 2018
Active, not recruiting
1
31
US
cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, CD123R(EQ)28zeta/EGFRt+ T cells, Anti CD123-CAR/CD28-costimulatory Lentiviral Vector-transduced Autologous T Lymphocytes, laboratory biomarker analysis, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Allogeneic CD123R(EQ)28zeta/EGFRt+ T Cells, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, Oforta, SH T 586
City of Hope Medical Center, National Cancer Institute (NCI), Mustang Bio, Inc.
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
12/24
12/24
NCT03009240: Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Active, not recruiting
1
30
US
Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Laboratory Biomarker Analysis, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
12/24
12/24
NCT03728335: Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant

Recruiting
1
35
US
Enasidenib Mesylate, 2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate, 2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1), AG-221 Mesylate, CC-90007, Enasidenib Methanesulfonate, Idhifa
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia
01/27
01/27
NCT04595162: A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Not yet recruiting
1
12
NA
GC019F
Peking University Third Hospital, Gracell Biotechnology Ltd.
B-cell Acute Lymphoblastic Leukemia
12/23
12/35
NCI-2018-01880, NCT03884998: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Active, not recruiting
1
27
US
Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
City of Hope Medical Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Richter Syndrome
07/24
07/24
NCT03560752: CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Active, not recruiting
1
34
US
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
01/22
06/24
NCT02675452: AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
142
Europe, Canada, Japan, US, RoW
AMG 176, Study Investigational Product (IP), Azacitidine, Itraconazole
Amgen
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
06/24
06/24
NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Active, not recruiting
1
37
Europe, Japan, US, RoW
VOB560, S65487, MIK665, S64315
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
07/24
07/24
NCT05665114: Natural Killer(NK) Cell Therapy in r/r AML

Recruiting
1
18
RoW
QN-030a, Cyclophosphamid, Fludarabine, Cytarabine, VP-16
Zhejiang University, Hangzhou Qihan Biotech Co.,Ltd.
AML, Adult
12/23
12/25
NCT05665075: Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Recruiting
1
19
RoW
QN-023a, Cyclophosphamid, Fludarabine, Cytarabine, VP-16
Zhejiang University, Hangzhou Qihan Biotech Co.,Ltd.
AML, Adult
12/23
12/25
NCT03494569: Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Recruiting
1
36
US
Fludarabine, Fluradosa, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813, Total Marrow Irradiation
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, Minimal Residual Disease, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
11/28
11/28
NCT05222984: Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Active, not recruiting
1
17
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
07/24
01/25
INA03, NCT03957915: Study of Escalating Doses of Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia

Recruiting
1
34
Europe
INA03 administration
Institut Paoli-Calmettes, INATHERYS
Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukaemia Recurrent, Mixed Phenotype Acute Leukemia
12/23
12/23
NCT05722171: Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
10
RoW
gdT cell injection targeting B7-H3 chimeric antigen receptor, UTAA06 injection
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia
12/23
12/24
NCT04609826: A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Active, not recruiting
1
153
Europe, RoW
JNJ-74856665, AZA, VEN
Janssen Research & Development, LLC
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
07/24
07/24
NCT02153580: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Active, not recruiting
1
37
US
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, CD19R(EQ)28zetaEGFRt+ Tn/mem Cells, CD19R(EQ)28zetaEGFRt+ Tn/Tmem, Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586
City of Hope Medical Center, National Cancer Institute (NCI)
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
12/24
12/24
NCT03467386: Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia

Recruiting
1
18
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total Marrow Irradiation
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia
12/24
12/24
RIVER-51, NCT04021368: RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Active, not recruiting
1
112
Europe, US
RVU120(SEL120)
Ryvu Therapeutics SA
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
12/24
12/24
NCT04281199: TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT

Active, not recruiting
1
20
US
Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, stem cell transplantation, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Tomotherapy, helical tomotherapy, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, Volume Modulated Arc Therapy, VMAT
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Leukemia, Myelodysplastic Syndrome
12/24
12/24
NCT05548088: LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Not yet recruiting
1
10
NA
LILRB4 STAR-T cells
Peking University People's Hospital, Beijing Qingyi Taike Pharmaceutical Technology Co., Ltd
Relapsed/Refractory Acute Myeloid Leukemia
12/23
08/24
NCT06201247: Off-the-shelf CD123 CAR-NK for R/R AML

Recruiting
1
12
RoW
JD123 injection
Peking University People's Hospital, Beijing JD Biotech Co. LTD.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
06/25
06/25
NCI-2018-01194, NCT03132454: Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Recruiting
1
54
US
Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
12/24
12/24
NCT03041688: Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Recruiting
1
58
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
06/26
06/26
NCI-2018-00159, NCT03447808: Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting
1
15
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pharmacological Study
Jennifer Woyach
Chronic Lymphocytic Leukemia
12/24
12/24
NCI-2019-01558, NCT03896269: CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recruiting
1
38
US
Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory High Risk Myelodysplastic Syndrome
12/24
12/24
APG-2575-CN-001, NCT03913949: A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Active, not recruiting
1
74
RoW
APG-2575
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
12/24
12/25
NCI-2019-03272, NCT03874052: Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
31
US
Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Brian Druker, AbbVie, Incyte Corporation, Oregon Health and Science University
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/24
12/24
NCT03892044: Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Completed
1
7
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, INK-1197, IPI-145, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
David Bond, MD
Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Richter Syndrome, Small Lymphocytic Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
02/24
02/24
NCI-2019-03203, NCT03989466: Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Active, not recruiting
1
15
US
Alemtuzumab, Anti-CD52 Monoclonal Antibody, Campath, Campath-1H, LDP-03, Lemtrada, MabCampath, Monoclonal Antibody Campath-1H, Itacitinib, INCB 039110, INCB-039110, INCB039110
M.D. Anderson Cancer Center
Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
12/26
12/26
NCT03983824: Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Suspended
1
48
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide Phosphate, Etopophos, Mitoxantrone Hydrochloride, CL 232315, DHAD, DHAQ, Dihydroxyanthracenedione Dihydrochloride, Mitoxantrone Dihydrochloride, Mitoxantroni Hydrochloridum, Mitozantrone Hydrochloride, Mitroxone, Neotalem, Novantrone, Onkotrone, Pralifan, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib
National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
06/25
06/25
NCT04220684: Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

Recruiting
1
21
US
Cytarabine Hydrochloride, Ara-C HCl, Arabinosylcytosine Hydrochloride, Aracytidine Hydrochloride, CHX-3311, Cytosar Hydrochloride, Cytosine Arabinosine Hydrochloride, U-19920A, Fludarabine, Fluradosa, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells, (mbIL21)-expanded Haploidentical NK Cells, Donor mbIL21-expanded NK Cells, mbIL21-expanded Haploidentical NK Cells
Sumithira Vasu, Kiadis Pharma
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/24
12/24
PBLTT52CAR19, NCT04557436 / 2019-003462-40: TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)

Completed
1
9
Europe
PBLTT52CAR19
Great Ormond Street Hospital for Children NHS Foundation Trust, University College, London
B Acute Lymphoblastic Leukemia
03/24
03/24
NCT04375631: CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recruiting
1
120
US
Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Nivestym, Filgrastim-aafi, Filgrastim-ayow, Releuko, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, stem cell transplantation, Hematopoietic Stem Cell Infusion, Mitoxantrone, Dihydroxyanthracenedione, Mitozantrone, Mycophenolate Mofetil, Cellcept, MMF, Mycophenolate Sodium, ERL 080, ERL 080A, Socium Mycophenolate, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Idarubicin, 4-DMDR, Fludarabine, Fluradosa, 9-Beta-D-arabinofuranosyl-2-fluoroadenine, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Echocardiography, EC, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
12/25
12/27
iVAC-XS15-CLL01, NCT04688385: Personalized Multi-peptide Vaccination in CLL Patients

Active, not recruiting
1
20
Europe
Multipeptide Vaccine+ XS15
University Hospital Tuebingen
Chronic Lymphocytic Leukemia
12/24
12/24
NCT05471323: Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML

Recruiting
1
36
RoW
RC1012 injection (allo-DNT cells)
Guangdong Ruishun Biotech Co., Ltd, First Affiliated Hospital of Zhejiang University
Acute Myeloid Leukemia
12/23
12/24
NCT05434312: TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Recruiting
1
90
RoW
TGRX-678
Shenzhen TargetRx, Inc., Peking University People's Hospital
Chronic Myelogenous Leukemia
12/24
06/25
NCT04825496: Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
1
18
RoW
ssCART-19 Cells, Fludarabine, FA, Cyclophosphamide, CTX
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University
Relapsed or Refractory Acute Lymphoblastic Leukemia
12/23
12/24
NCT04874480: Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Active, not recruiting
1
9
US
Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Tegavivint, BC 2059, BC-2059, BC2059, Tegatrabetan
M.D. Anderson Cancer Center
Recurrent Leukemia, Refractory Leukemia
12/24
12/24
NCT04848064: Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recruiting
1
12
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Mogamulizumab, Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW-0761, Mogamulizumab-kpkc, Poteligeo, Natural Killer Cell Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
John Reneau
Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
12/24
12/24
NCT05418088: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recruiting
1
36
US
Anti-CD19/CD20/CD22 CAR T-Cells, Anti-CD19/20/22 Chimeric Antigen Receptor T-Cells, CD19/CD20/CD22-targeted CAR-T Cells, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586
Sumithira Vasu, National Cancer Institute (NCI)
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent High Grade B-Cell Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory High Grade B-Cell Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
04/25
07/26
NCT05501899: Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

Recruiting
1
20
US
Levocarnitine, Carnitor®
Children's Hospital of Orange County, University of California, Irvine
Acute Lymphoblastic Leukemia, Hepatotoxicity
12/23
12/23
NCT01044069: Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Checkmark In adult ALL at ASCO 2016
Jun 2016 - Jun 2016: In adult ALL at ASCO 2016
Checkmark Adult ALL at ASH 2015
Dec 2015 - Dec 2015: Adult ALL at ASH 2015
Checkmark For adult ALL at ASCO 2015
More
Active, not recruiting
1
93
US
gene-modified T cells targeted
Memorial Sloan Kettering Cancer Center
Leukemia, Acute Lymphoblastic Leukemia
01/25
01/25
 

Download Options